Assessment of Endocan Serum Levels in Patients With Behcet Disease

Study Overview
=================
Brief Summary
-----------------
The aim of our study was to assess serum endocan levels in patients with Behcet disease and to correlate it with various disease clinical and laboratory parameters of disease activity as well as carotid intima media thickness.

Detailed Description
-----------------
This study will be carried out on two groups: • Group (I): Forty two patients diagnosed to have Behcets disease fulfilling the International Criteria for BD . Group (II): including 42 age and sex matching healthy volunteers as control group. (A) Clinical evaluation Complete history taking. Thorough clinical examination including opthalmologic evaluation . Disease activity using The Behcet's disease current activity form (BD-DAF) . (B) Laboratory assessment: All patients will be subjected to the following measurements: ESR CRP CBC liver and kidney function tests d) Serum Endocan level e)triglycrides f) cholestrol C) carotid intima media thickness

Official Title
-----------------
Assessment of Endocan Serum Levels in Patients With Behcet Disease: Relation to Clinical Parameters and Disease Status

Conditions
-----------------
Behçet

Intervention / Treatment
-----------------
* Diagnostic Test: measurement of serum endocan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with Behcets disease fulfilling the International Criteria for BD . Exclusion Criteria: infection malignancy other connective tissue disease chronic liver disease chronic kidney disease Diabetes mellitus hypertension hyperlipidemia

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Behçet group<br>Forty two patients diagnosed to have Behçet disease fulfilling the International Study Group Criteria for Behçet disease in whom measurement of serum endocan levels will be performed. | Diagnostic Test: measurement of serum endocan<br>* measurement of serum levels of endocan<br>* Other names: endothelial cell-specific molecule 1;|
| control group<br>including 42 age and sex matching healthy volunteers as control group in whom measurement of serum endocan levels will be performed. | Diagnostic Test: measurement of serum endocan<br>* measurement of serum levels of endocan<br>* Other names: endothelial cell-specific molecule 1;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the Behcet's disease current activity form (BDCAF) | One point is given to the presence of different organ involvement over the 4 weeks prior to assessment as follows: headache, mouth ulcers, genital ulcers, skin lesions , joint involvement , gastrointestinal symptoms , eye involvement , nervous system involvement , and major vessel involvement.The total score will be out of 12 and higher score indicates worse outcome. we will assess the relation between serum endocan level and BDCAF | : through study completion, an average of 6 months | 
| Erythrocyte sedimentation rate (ESR) | ESR measured in mm/1st hour by westergren method. we will assess the relation between serum endocan level and ESR | : through study completion, an average of 6 months | 
| C reactive protein (CRP) | CRP measured in mg/L using nephlometry. we will assess the relation between serum endocan level and CRP | : through study completion, an average of 6 months | 
| carotid intima media thickness | Color Doppler ultrasonography was performed for both common carotid arteries in a longitudinal orientation and measured with millimeter | : through study completion, an average of 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Behçet disease, endocan